Search results
Results from the WOW.Com Content Network
With Johnson & Johnson behind it, and with an additional $100 million invested in its development, the Palmaz stent was approved for use in peripheral arteries in 1991, followed by approval for use in coronary arteries in 1994; Johnson & Johnson quickly captured 90 percent of the market for stents and bought the patent outright from Palmaz ...
Stent technology improved rapidly, and in 1989 the Palmaz-Schatz balloon-expandable intracoronary stent was developed. [24] [25] Initial results with the Palmaz-Schatz stents were excellent when compared to balloon angioplasty, with a significantly lower incidence of abrupt closure and peri-procedure heart attack. [26]
Johnson & Johnson was founded in 1886 by three brothers, Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson, selling ready-to-use sterile surgical dressings. In 2023, the company split-off its consumer healthcare business sector into a new publicly traded company, Kenvue .
Researchers from the University of British Columbia have developed a "groundbreaking coating" that could make blood-contacting devices safer. Dr. Jayachandran Kizhakkedathu discusses the benefits.
Though several doctors have been credited with the creation of the stent, the first FDA-approved stent in the U.S. was created by Richard Schatz and coworkers. Named the Palmaz-Schatz (Johnson & Johnson), it was developed in 1987. [21] To further reduce the incidence of restenosis, the drug-eluting stent was introduced in 2003. [22]
How are you holding up? Are you over it? I'm over it. I'm fine. At least, at times I think that. It's obviously not what I wanted but that's life.
From E. coli traced to slivered onions on McDonald's Quarter Pounders to mass recalls of frozen waffles due to listeria risk, foodborne illness seems ever-present in the headlines.
Most current FDA-approved drug-eluting stents use sirolimus (also known as rapamycin), everolimus and zotarolimus. Biolimus A9-eluting stents, which utilize biodegradable polymers, are approved outside the U.S. [27] Newer-generation PCI technologies aim to reduce the risk of late stent thrombosis or other long-term adverse events.